Showing results (171-180 of 368) with videos related to
Sort By:
Pageof 37
Diabetes, Obesity & Metabolism|April 1, 2020
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trialSubodh Verma, Abhinav Sharma, Bernard Zinman, et al.Diabetes Care|April 24, 2010
The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapyJulio Rosenstock, Salomon Banarer, Vivian A Fonseca, et al.International Journal of Obesity (2005)|October 23, 2019
Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRBElizabeth Sanchez-Rangel, Jean-Dominique Gallezot, Catherine W Yeckel, et al.BMJ Open Diabetes Research & Care|December 3, 2014
The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarctionSuzanne V Arnold, Kasia J Lipska, Silvio E Inzucchi, et al.The New England Journal of Medicine|September 18, 2015
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesBernard Zinman, Christoph Wanner, John M Lachin, et al.Diabetes, Obesity & Metabolism|July 3, 2023
The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetesMikkel Jürgens, Morten Schou, Philip Hasbak, et al.Circulation. Cardiovascular Quality and Outcomes|June 14, 2012
Glucose variability and mortality in patients hospitalized with acute myocardial infarctionKasia J Lipska, Lakshmi Venkitachalam, Kensey Gosch, et al.European Heart Journal|October 12, 2017
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trialDavid Fitchett, Javed Butler, Philippe van de Borne, et al.JAMA Neurology|February 9, 2019
Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical TrialJ David Spence, Catherine M Viscoli, Silvio E Inzucchi, et al.Journal of the American College of Cardiology|November 1, 2023
Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1cRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.Pageof 37